- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, TGN-1062 / TGen
TGN-1062, a dual CDK7 and FLT3 Inhibitor, shows potent anti-AML activity and synergizes with Venetoclax (Section 18) - Mar 5, 2024 - Abstract #AACR2024AACR_8363; Since its approval venetoclax, a BCL2 inhibitor, has been the standard treatment for older patients in combination with a hypomethylating agent (HMA), such as azacitidine or decitabine, with a 76% complete response (CR). Targeting CDK7 with TGN-1062 in combination with venetoclax or an HMA is a promising therapeutic approach for treatment of AML and needs further investigation.
|